Certara on Bioeconhttps://en.bioecon.ru/companies/certara/Recent content in Certara on BioeconHugoen-USWed, 22 Jul 2026 21:55:35 +0700Toxics screening (toxicomics, service)https://en.bioecon.ru/technology/toxics-screening-toxicomics-service/Wed, 22 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/toxics-screening-toxicomics-service/Contract safety assessment that takes a drug candidate from in-silico ADMET triage through in-vitro panels (hepatotoxicity, hERG, CYP induction) to GLP in-vivo studies, delivering the IND-enabling toxicity package regulators require — now augmented by toxicogenomics and virtual control groups.Patient digital twins & in-silico trialshttps://en.bioecon.ru/technology/patient-digital-twins-in-silico-trials/Mon, 20 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/patient-digital-twins-in-silico-trials/Computational patient models and virtual trial simulations used to reduce, accelerate or de-risk clinical development — AI-generated synthetic control arms, physiologically-based pharmacokinetic modeling, preclinical-to-clinical translation AI and causal-AI virtual patient simulation: Unlearn.AI, Certara and VeriSIM Life in the US, and Novadiscovery (Nova In Silico) in France.